

IN THE CLAIMS:

Claims 1, 3, 9-12, 19, 21, 31-34, and 38 have been amended herein. Claims 2, 6, 8, 11, 20, and 22-23 have been cancelled herein. All of the pending claims 1 through 41 are presented below. This listing of claims will replace all prior versions and listings in the application. Please enter these claims as amended.

Listing of the Claims

1. (Currently Amended) A method of determining whether a treatment is effective in changing a status of ~~a certain set of target~~ Kaposi's Sarcoma tumor cells in an individual said method comprising:
obtaining a sample from said individual after initiating said treatment; ~~and~~
determining whether said sample comprises a change in level of an expression products of
at least one marker gene- SEQ ID NOS: 72 and 81; and
wherein said change in the level of the expression products indicates whether said treatment is effective in changing the status of said tumor cells.
2. (Cancelled)
3. (Currently Amended) The method according to claim 1, wherein said sample comprises at least one of said ~~target~~ Kaposi's Sarcoma tumor cells.
4. (Previously Presented) The method according to claim 1, wherein said sample is obtained within one week of initiating said treatment.
5. (Previously Presented) The method according to claim 1, wherein said sample is obtained within two days of initiating said treatment.
6. (Cancelled)

7. (Withdrawn) The method according to claim 1, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31.
8. (Cancelled)
9. (Currently Amended) The method according to claim 1, wherein expression of ~~said at least one marker gene~~ SEQ ID NOS: 72 and 81 is quantified.
10. (Currently Amended) The method according to claim 1, further comprising comparing expression of ~~said at least one marker gene~~ SEQ ID NOS: 72 and 81 with a reference value.
11. (Cancelled)
12. (Currently Amended) A method of detecting an expression products of SEQ ID NOS: 72 and 81 ~~a marker gene~~ said method comprising:
obtaining a sample from an individual;
introducing ~~[[a]]~~ nucleic acids to said sample, said nucleic acids comprising:
selected from the group consisting of SEQ ID NOS:1-31 and 65-82 SEQ ID NO: 72 and
SEQ ID NO: 81, or a part or analogue thereof;
~~determining whether~~ hybridizing said nucleic acids hybridizes to said expression products in said
sample; and
detecting the hybridized molecules.
13. (Withdrawn) A method of detecting an expression product of a marker gene comprising:
incubating a proteinaceous molecule to a sample from an individual, said proteinaceous molecule
capable of specifically binding a protein encoded by a nucleic acid selected from the
group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof; and
detecting binding between said proteinaceous molecule and said protein.

14. (Previously Presented) The method according to claim 12, further comprising determining the presence of a tumor cell in said individual.
15. (Previously Presented) The method according to claim 12, further comprising determining the presence of a site of angiogenesis in said individual.
16. (Previously Presented) The method according to claim 12, further comprising determining whether a treatment is effective in changing the status of a certain set of target cells in said individual.
17. (Previously Presented) The method according to claim 12, further comprising determining whether a treatment is effective in counteracting a tumor in said individual.
18. (Previously Presented) The method according to claim 14, wherein said tumor cell comprises Kaposi's Sarcoma.
19. (Currently Amended) A method for determining whether an individual possesses a Kaposi's Sarcoma tumor cell and/or a site of angiogenesis, said method comprising:
obtaining a sample from said individual; and
determining whether said sample comprises ~~an~~ expression products of SialoAdhesin and TIE 1;
and of at least one marker gene
wherein the levels of said expression products indicates the presence or absence of a tumor cell
and/or a site of angiogenesis.
20. (Cancelled)

21. (Currently Amended) A method of determining whether an individual possesses a ~~non-hemopoietic tumor cell~~ and/or a site of angiogenesis, said method comprising determining whether a hemopoietic cell from said individual comprises an altered amount of ~~an~~ expression products of ~~a marker gene~~ SEQ ID NOS: 72 and 81 as compared with [[a]] reference values.
22. (Cancelled)
23. (Cancelled)
24. (Previously Presented) The method according to claim 21, wherein said hemopoietic cell comprises a peripheral blood mononuclear cell.
25. (Withdrawn) A method of determining whether a treatment is effective in altering an angiogenic process in an individual comprising:
obtaining a first sample from said individual before initiating said treatment;
obtaining a second sample from said individual after initiating said treatment; and
comparing expression of an expression product of at least one marker gene in said first sample
and said second sample.
26. (Withdrawn) The method according to claim 25, wherein said treatment comprises counteracting angiogenesis in said individual.
27. (Withdrawn) The method according to claim 25, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

28. (Withdrawn) The method according to claim 25, wherein said treatment involves the use of at least one drug selected from the group consisting of 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC44047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat, Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470, and Vitaxin.

29. (Previously Presented) The method according to claim 1, wherein said sample is a blood sample.

30. (Previously Presented) The method according to claim 1, wherein said sample comprises a peripheral blood mononuclear cell.

31. (Currently Amended) The method according to claim 1, wherein said expression products ~~comprises one of SEQ ID NOS:6, 30, 72 and 81, or a part of analogue~~ comprise SEQ ID NO: 72 and SEQ ID NO: 81 thereof.

32. (Currently Amended) A method of detecting angiogenesis comprising detecting peripheral blood mononuclear cell expression of ~~at least one of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a parts or analogues~~ SEQ ID NO: 72 and SEQ ID NO: 81 thereof.

33. (Currently Amended) A method of determining the presence of a Kaposi's Sarcoma tumor cell in an individual comprising:
obtaining a sample from said individual; ~~and~~
detecting levels of peripheral blood mononuclear cell expression in the sample of at least one
of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a parts or analogues SEQ ID NO: 72 and
SEQ ID NO: 81 thereof; and
using the levels of detected expression to determine the presence or absence of a tumor in an
individual.

34. (Currently Amended) A method of diagnosing presence of disease comprising comparing expression of ~~an~~ isolated sequences of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or ~~[[a]]~~ parts or analogues thereof, in an individual to ~~[[a]]~~ reference values.

35. (Withdrawn) A diagnostic kit comprising a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof, and a proteinaceous molecule capable of specifically binding a protein encoded by said nucleic acid or said part or analogue thereof.

36. (Withdrawn) The diagnostic kit according to claim 35, further comprising at least one of SEQ ID NOS:6, 18, 30, 66, 72, and 81, or a part or analogue thereof.

37. (Withdrawn) A method of determining whether a treatment is effective in changing the status of a certain set of target cells in an individual and/or altering an angiogenic process in an individual, said method comprising:
providing the diagnostic kit according to claim 35;
obtaining a sample from said individual; and
detecting the presence of an expression product of at least one marker gene in said sample.

38. (Currently Amended) A method of determining whether an individual possesses a Kaposi's Sarcoma tumor cell and/or a site of angiogenesis, said method comprising:
~~providing the diagnostic kit according to claim 35;~~ providing a diagnostic kit comprising:
nucleic acids comprising SEQ ID NO: 72 and SEQ
ID NO:81; and/or
proteinaceous molecules capable of specifically bind to SialoAdhesin or TIE 1; and
obtaining a sample from said individual; ~~and~~
quantifying ~~[[an]]~~ expression products of ~~at least one marker gene~~ SEQ ID NOS: 72 and 81 in
said sample; and
using the quantification of SEQ ID NOS: 72 and 81 to determine whether the individual posses a
tumor cell and/or a site of angiogenesis.
39. (Withdrawn) A method for identifying desired drug activity comprising:
determining an expression pattern of a marker gene in cells;
incubating said cells with an expression product of a gene comprising one of SEQ ID NOS:1-31
and 65-82; and
detecting an alteration in said expression pattern of said marker gene after said incubating.
40. (Withdrawn) A compound capable of altering the activity of at least one of SEQ ID
NOS:66, 72, and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell.
41. (Withdrawn) A method of preparing a medicament comprising:
identifying a compound capable of altering the activity of at least one of SEQ ID NOS:66, 72,
and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell; and
incorporating said identified compound into a medicament.